The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers

Ann Oncol. 2020 Mar;31(3):430-434. doi: 10.1016/j.annonc.2019.11.019. Epub 2019 Dec 11.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Camptothecin / analogs & derivatives
  • Cell Line, Tumor
  • Humans
  • Immunoconjugates* / therapeutic use
  • Neoplasms* / drug therapy
  • Receptor, ErbB-2 / genetics
  • Trastuzumab

Substances

  • Immunoconjugates
  • trastuzumab deruxtecan
  • Receptor, ErbB-2
  • Trastuzumab
  • Camptothecin